Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emerik Osterlund has a total of 215 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical impact of prospective circulating tumour DNA testing for minimal residual disease in colorectal cancer: the INTERCEPT programme experience

    by Giulia Maddalena, Kathryn Aziz, Ryan Sun, Timothy E Newhook, Kristin Alfaro, Andrew Bowling, Dylan N Gil, Ramy S Behman, Mahmoud Yousef, Y Nancy You, et al.

    Background The impact of circulating tumour DNA (ctDNA) detection, which informs minimal residual disease (MRD) after curative treatment, remains debated especially for stage IV patients. Objective The study objectives were to evaluate the prognostic role of MRD and to estimate lead time (LT) at different timepoints when adopting longitudinal MRD testing. Design INTERCEPT, is a prospective, observational cohort study of stage II–IV patients with colorectal cancer receiving curative-intent treatment who are longitudinally monitored using tissue-informed MRD assays as part of routine clinical care. Results Study results confirm the prognostic value of MRD, also beyond 12 months from surgery, with higher recurrence incidence in MRD-positive stage II–III patients than in MRD-negative stage IV patients (pConclusion ctDNA testing provides a framework for risk stratification and defines temporal windows that may inform future interventional strategies. Prospective interventional studies are required to define clinical utility and optimal implementation.

  • Open Access

    Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients

    by Guglielmo Vetere, Emerik Osterlund, Mahmoud M G Yousef, Songwit Payapwattanawong, Giulia Maddalena, Jumanah Alshenaifi, Kristin D Alfaro, Mark Knafl, Van K Morris, Christine M Parseghian, et al.

    Background: Immune checkpoint inhibitors (ICIs) have limited efficacy in proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC). However, selected patients with specific metastatic patterns may derive benefit. Methods: Patients with chemorefractory pMMR/MSS mCRC treated with ICI-based regimens were retrospectively identified. A comparison cohort treated with trifluridine/tipiracil±bevacizumab, regorafenib, or fruquintinib as standard of care (SOC) was generated through 1:1 propensity score matching by age, sex, Eastern Cooperative Oncology Group performance status (ECOG PS), liver metastases (present/absent), and RAS/BRAF status. Overall survival (OS) was compared using Cox regression. Results: A total of 354 patients treated with ICIs and 354 treated with SOC were matched. Median age was 55 years, 52% male, 32% ECOG PS 0, 30% right-sided, and 69% RAS mutated in both groups, while 61% and 60% had liver metastases, respectively. Median OS (mOS) was 10.8 months with ICIs and 9.0 months with SOC (HR 0.76, 95% CI 0.64 to 0.92, p=0.004). In patients without liver metastases, mOS was longer with ICIs than SOC (19.1 vs 13.2 months, HR 0.59, 95% CI 0.43 to 0.80, pRAS / BRAF status were not associated with OS. Treatment with ICIs, absence of liver metastases, one prior line of therapy, less than three metastatic sites, and ECOG PS 0 were associated with the most favorable outcomes in univariable and multivariable models. Conclusions: In chemorefractory pMMR/MSS mCRC without liver metastases, ICI-based regimens yielded longer OS than SOC. Further investigation of ICIs in this patient population is warranted.

  • Open Access

    Cost-effectiveness analysis of operative versus non-operative management of colorectal cancer metastases in the Finnish RAXO Study

    by Joel Kontiainen, Kaisa Lehtomäki, Timo Muhonen, Jarmo Hahl, Iiro Toppila, Tuija Poussa, Emerik Osterlund, Eetu Heervä, Hanna Stedt, Raija Kallio, et al.

    Background and purpose: Cancer therapies place an increasing financial burden on societies. In metastatic colorectal cancer (mCRC), an optimised curative-intent treatment combines metastasectomy, local ablative therapy, and perioperative systemic anti-cancer therapy (SACT) under multidisciplinary team guidance. The resource-intensive operative treatment strategy results in better survival than a non-operative approach with SACT only. The cost-effectiveness of the strategy including operative treatment has not been investigated in the era of modern treatment options.Patient/material and methods: A Markov model was developed to estimate lifetime healthcare costs and quality-adjusted life-years (QALYs). Patients receiving operative treatment, including metastasectomy along with SACT, and those receiving non-operative treatment with SACT only, were identified from the prospective Finnish RAXO study that recruited 1,086 patients between 2012 and 2018. Cost-effectiveness analyses and sensitivity analyses were conducted from the healthcare payer’s perspective using 2023 cost levels.Results: The mean lifetime costs (158,309€) for patients with an operative treatment produced 6.57 life years and 5.91 QALYs according to the Markov model. The non-operative treatment group had costs of 77,182€, producing 1.99 life years and 1.74 QALYs. The incremental cost-effectiveness ratio (ICER) was 19,455€/QALY, with the caveat that more favourable characteristics were present in the operative group. In probabilistic sensitivity analyses with a willingness-to-pay threshold of 30,000€/QALY, the operative treatment group had an 81% probability of being cost-effective. The results were robust in adjusted sensitivity analyses, including propensity score matched subgroups.Interpretation: An operative treatment strategy is cost-effective at a commonly referenced acceptability threshold.

  • Open Access

    KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts

    by Emerik Osterlund, Ari Ristimäki, Luís Nunes, Soili Kytölä, Sonja Aho, Eetu Heervä, Aki Uutela, Kaisa Lehtomäki, Hanna Stedt, Päivi Halonen, et al.

    Background: KRAS and NRAS mutations (mt) are drivers in metastatic colorectal cancer (mCRC). We studied frequencies, characteristics, treatments, and outcomes of different KRAS mt and NRAS mt in population-based and real-world settings. Methods: Three Nordic cohorts were combined and molecularly characterised for KRAS , NRAS , and BRAF -V600E hotspot mutations. Results: Of 2649 mCRC patients, 2118 were molecularly classified. KRAS mt were seen in 49%, NRAS mt in 4%, RAS& BRAF wt in 33%, and BRAF -V600Emt in 14%. No differences in clinical characteristics were observed between KRAS mt and NRAS mt. Median overall survival (OS) was longest among RAS& BRAF wt, intermediate among KRAS mt and NRAS mt, and shortest among BRAF -V600Emt (28.3 vs 21.4 vs 26.3 vs 9.2 months, respectively). Among the eight most common KRAS mt, the only clinical difference was that KRAS -G12S had more distant lymph node metastases (38% vs 18–27%, p = 0.041). KRAS -G12S had shorter OS than KRAS -G12V, KRAS -G12C, KRAS -G12A, and KRAS -G13D. The differences were smaller in treatment groups but withstood in multivariable models. The three most common NRAS mt did not differ clinically. Conclusion: KRAS mt and NRAS mt are seen in 49% and 4% of mCRC, respectively. No clinically relevant differences were observed between different RASmt. KRAS mt is a common subgroup for which the outcome hopefully can be improved with newly developed drugs.


  • Open Access

    Evaluation of Bridge Capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients

    by Aparna Ganesan, Anttoni Korkiakoski, Simona Adamusová, Anna Musku, Tuula Rantasalo, Nea Laine, Emma Andersson, Emerik Osterlund, Ali Ovissi, Päivi Halonen, et al.

    Colorectal cancer (CRC) is the second leading cause of cancer-related deaths, often presenting at an advanced stage with significant molecular heterogeneity. This is the first study to evaluate the performance of a novel next-generation sequencing (NGS)-based Bridge Capture technology for mutation profiling and minimal residual disease detection in circulating tumor (ct)DNA from metastatic colorectal cancer (mCRC) patients. Its performance was compared to those of droplet digital PCR (ddPCR), Ion AmpliSeq Cancer Hotspot Panel v2, and Idylla ctKRAS Mutation Assay. Eighty serial plasma samples from ten mCRC patients were analyzed by Bridge Capture and ddPCR, demonstrating a very strong correlation in variant allele frequency (VAF) values (rs = 0.86). The concordance of Bridge Capture with ddPCR (kappa = 0.70) and Idylla (kappa = 0.79) showed substantial agreement. A subset of samples (n = 10) was analyzed using the Ion AmpliSeq NGS-panel and both methods identified 15 driver mutations with strong correlation of VAF values (rs = 0.74). Additionally, Bridge Capture identified several oncogenic mutations beyond those detected by Ion AmpliSeq, highlighting its comprehensive profiling capability. The scalability of Bridge Capture was validated using an expanded panel and synthetic DNA targets, showing a strong linear correlation between observed and expected VAF values. This study demonstrates the scalability and accuracy of the Bridge Capture platform, and its potential to enhance mutation detection and clinical decision-making using ctDNA samples from patients with mCRC.


  • Open Access

    Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort

    by Emerik Osterlund, Klara Hammarström, Luís Nunes, Lucy Mathot, Artur Mezheyeuski, Tobias Sjöblom, Bengt Glimelius

    Background: Metastatic colorectal cancer (mCRC) patients in trials are selected. The aim was to study mCRC features population-based. Methods: All 765 mCRC patients in the Uppsala region, Sweden, 2010–2020 were identified and analysed for RAS (n = 356/708) and BRAF-V600E (n = 123/708) mutations (mt) and deficient mismatch repair (dMMR, n = 58/643). Results: Right colon primary tumours were associated with BRAF-V600Emt and dMMR and had worse median overall survival (mOS) than left colon or rectal mCRC. RAS&BRAF wildtype (wt) and proficient MMR were seen in 22%, 45%, and 31% of right colon, left colon, and rectum, respectively. Patients with right colon primaries received best supportive care only more often (34% vs 25% vs 24%) and metastasectomy less often (21% vs 31% vs 33%) than left colon and rectal primaries. In molecularly homogeneous subgroups (RAS&BRAFwt/RASmt/BRAF-V600Emt/dMMR) no difference in mOS were seen between right and left colon primaries, whereas rectal primaries had better mOS (26/15/8/9 vs 24/21/8/8 vs 32/23/6/NA months, respectively). This was also the case in homogenous treatment groups. Primary tumour location turned non-significant in multivariable OS analyses. Conclusions: The high variation of BRAF-V600Emt, RASmt, dMMR, and treatment allocation population-based per primary tumour location explain the poor outcome in right-sided cancers.


  • Open Access

    Representation of geriatric oncology in cancer care guidelines in Europe: a scoping review by the International Society of Geriatric Oncology (SIOG)

    by I. Pinker, I. Pinker, C. Lafont, C. Lafont, G. Liposits, G. Liposits, R. Vidra, R. Vidra, A.J. Cunquero-Tomás, A.J. Cunquero-Tomás, et al.


  • Top Cited Papers
    Open Access

    Prognostic genome and transcriptome signatures in colorectal cancers

    by Luís Nunes, Fuqiang Li, Meizhen Wu, Tian Luo, Klara Hammarström, Emma Torell, Ingrid Ljuslinder, Artur Mezheyeuski, Per-Henrik Edqvist, Anna Löfgren-Burström, et al.

    Colorectal cancer is caused by a sequence of somatic genomic alterations affecting driver genes in core cancer pathways1. Here, to understand the functional and prognostic impact of cancer-causing somatic mutations, we analysed the whole genomes and transcriptomes of 1,063 primary colorectal cancers in a population-based cohort with long-term follow-up. From the 96 mutated driver genes, 9 were not previously implicated in colorectal cancer and 24 had not been linked to any cancer. Two distinct patterns of pathway co-mutations were observed, timing analyses identified nine early and three late driver gene mutations, and several signatures of colorectal-cancer-specific mutational processes were identified. Mutations in WNT, EGFR and TGFβ pathway genes, the mitochondrial CYB gene and 3 regulatory elements along with 21 copy-number variations and the COSMIC SBS44 signature correlated with survival. Gene expression classification yielded five prognostic subtypes with distinct molecular features, in part explained by underlying genomic alterations. Microsatellite-instable tumours divided into two classes with different levels of hypoxia and infiltration of immune and stromal cells. To our knowledge, this study constitutes the largest integrated genome and transcriptome analysis of colorectal cancer, and interlinks mutations, gene expression and patient outcomes. The identification of prognostic mutations and expression subtypes can guide future efforts to individualize colorectal cancer therapy.


  • Prognostic and Predictive Factors in Metastatic Colorectal Cancer

    by Emerik Österlund

    The outcome for metastatic colorectal cancer (mCRC) patients has improved substantially in recent decades. This has chiefly been observed in study populations, and predominantly in left-sided prima ...

  • Open Access

    Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study)

    by Sonja Aho, Emerik Osterlund, Ari Ristimäki, Lasse Nieminen, Jari Sundström, Markus J. Mäkinen, Teijo Kuopio, Soili Kytölä, Annika Ålgars, Raija Ristamäki, et al.

    The primary tumor location (PTL) is associated with the phenotype, metastatic sites, mutations, and outcomes of metastatic colorectal cancer (mCRC) patients, but this has mostly been studied according to sidedness (right vs. left sided). We studied right colon vs. left colon vs. rectal PTL in a real-life study population (n = 1080). Health-related quality of life (HRQoL) was assessed multi-cross-sectionally with QLQ-C30, QLQ-CR29, EQ-5D, and 15D. A chi-square, Kaplan–Meier, and Cox regression were used to compare the groups. The PTL was in the right colon in 310 patients (29%), the left colon in 396 patients (37%), and the rectum in 375 patients (35%). The PTL was associated with distinct differences in metastatic sites during the disease trajectory. The resectability, conversion, and resection rates were lowest in the right colon, followed by the rectum, and were highest in the left colon. Overall survival was shortest for right colon compared with left colon or rectal PTL (median 21 vs. 35 vs. 36 months), with the same trends after metastasectomy or systemic therapy only. PTL also remained statistically significant in a multivariable model. The distribution of symptoms varied according to PTL, especially between the right colon (with general symptoms of metastases) and rectal PTL (with sexual- and bowel-related symptoms). mCRC, according to PTL, behaves differently regarding metastatic sites, resectability of the metastases, outcomes of treatment, and HRQoL.